Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

Recruiting

• Conditions: Transthyretin Amyloidosis; ATTR-CM; ATTRv-PN; ATTR; ATTR-Mixed; hATTR

• Registration Number: NCT06465810
• Lead Sponsor: AstraZeneca

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-5-13
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Inclusion Criteria:<br><br> - Patient willing and able to provide written informed consent to participate in the<br> study<br><br> - Confirmed diagnosis of amyloid transthyretin (ATTR) amyloidosis<br><br> - Aged =18 years at the time of signing the informed consent<br><br> - Patient willing and able to participate in collection of electronic patient reported<br> outcomes (PROs)<br><br>Exclusion Criteria:<br><br> - Concurrent participation in any interventional trial for ATTR amyloidosis<br><br> - Involvement in the planning and/or conduct of the current study<br><br> - Patients with evidence of primary or light chain amyloidosis (AL) or serum protein A<br> amyloidosis (AA)<br><br> - Asymptomatic patients with ATTR amyloidosis and asymptomatic ATTR mutation carriers

Exclusion Criteria

Not provided

Study & Design

• Study Type: Observational
• Study Design: Not specified